News
Jul 15, 2023
Date & Time
Saturday, July 15, 2023 12:00 PM ET
Description
Please join ASG on Saturday, July 15th from 12:00 pm - 3:00 pm ET for the next webinar on ATTRv and…
Jul 11, 2023
July 11, 2023 | Cardiovascular Business
For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in…
Jun 28, 2023
As part of their continued dedication to raising awareness about hATTR amyloidosis and the impact the disease has on those affected, Alnylam Pharmaceuticals is…
Jun 24, 2023
When:
Saturday, June 24, 2023 from 8:00am to 3:00pm EDT
Where:
Columbia University Irving Cancer Research Center
1130 St. Nicholas Avenue
New York City, NY 10032…
May 08, 2023
National Amyloidosis Day takes place on the 8th of May each year with the aim of raising awareness for Amyloidosis. Amyloidosis is a rare disease that occurs when a…
Apr 24, 2023
CARLSBAD, Calif., April 24, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Incexternal link, opens in a new tab. (Nasdaq: IONSexternal link, opens in a new tab) today…
Feb 22, 2023
April Johnson Stearns, Founder, and Editor-in-Chief, of WILDFIRE Magazine is leading a workshop for anyone interested in using their voice to advocate for…
Aug 03, 2022
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the APOLLO-B Phase 3 study of patisiran, an…
Jul 12, 2021
Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…
Apr 17, 2020
The American Society of Nuclear Cardiologyexternal link, opens in a new tab designates this live activity for a maximum of 4 CME Credits(tm). Physicians should…